Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Islet Sciences gets rights to remogliflozin from BHV

Executive Summary

BHV Pharma Inc. (Brighthaven Ventures) licensed Islet Sciences Inc. exclusive worldwide rights--excluding Japan, Korea, Taiwan, China, and Latin America--to develop and commercialize its Phase IIb SGLT2 inhibitor remogliflozin etabonate for Type II diabetes and nonalcoholic steatohepatitis (NASH).
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Intra-Biotech Deal
    • R&D and Marketing (Licensing)

Related Companies

UsernamePublicRestriction

Register